Gen­zyme vet David Meek­er takes helm at stealthy KSQ with $76M and a new map for drug dis­cov­ery

David Meek­er left Gen­zyme last April af­ter a 23-year run, in­clud­ing six years as pres­i­dent af­ter Sanofi stepped in to buy the land­mark biotech six years ago. And as it turns out, in­stead of re­tir­ing and end­ing the sto­ry, his ca­reer was shift­ing in­to a brand new chap­ter.

To­day, five months lat­er, af­ter adding a string of biotech board po­si­tions to his sched­ule, Meek­er has land­ed his next big gig in biotech. And like many of his col­leagues ahead of him, he’s tran­si­tion­ing from his for­mal ex­it from the Big Phar­ma world to the thriv­ing cos­mos of biotech star­tups.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.